Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:TZYM
- CUSIP: N/A
- Web: N/A
- Trailing P/E Ratio:
- Foreward P/E Ratio: -1.28
- P/E Growth:
Frequently Asked Questions for Ocera Therapeutics (NASDAQ:TZYM)
What is Ocera Therapeutics' stock symbol?
Ocera Therapeutics trades on the NASDAQ under the ticker symbol "TZYM."
Who are some of Ocera Therapeutics' key competitors?
Some companies that are related to Ocera Therapeutics include Orange Belgium (MBSRF), Abengoa SA (ABGB), Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft (MSFT), Amazon.com (AMZN), Facebook (FB), Premier Foods Spon (PRRFY), Berkshire Hathaway (BRK-A), Nestle SA (NSRGY), Roche Holding (RHHBY), RDS-A (RDS-A), Comcast (CMCSA), Intel (INTC), Cisco Systems (CSCO), LVMH Moet Hennessy Louis Vuitton SE (LVMUY) and Inditex (IDEXY).
Who owns Ocera Therapeutics stock?
How do I buy Ocera Therapeutics stock?
Shares of Ocera Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ocera Therapeutics stock cost?
One share of Ocera Therapeutics stock can currently be purchased for approximately $0.48.
Consensus Ratings for Ocera Therapeutics (NASDAQ:TZYM) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Ocera Therapeutics (NASDAQ:TZYM)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Ocera Therapeutics (NASDAQ:TZYM)Earnings History by Quarter for Ocera Therapeutics (NASDAQ:TZYM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/28/2013||Q4 2012||($0.30)||($0.18)||$1.70 million||$1.60 million||View||N/A|
|11/8/2012||Q312||($0.29)||($0.16)||$1.99 million||$1.80 million||View||N/A|
Earnings Estimates for Ocera Therapeutics (NASDAQ:TZYM)
Current Year EPS Consensus Estimate: $-0.170 EPS
Next Year EPS Consensus Estimate: $-0.370 EPS
Dividend History for Ocera Therapeutics (NASDAQ:TZYM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Ocera Therapeutics (NASDAQ:TZYM)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Ocera Therapeutics (NASDAQ:TZYM)
Latest Headlines for Ocera Therapeutics (NASDAQ:TZYM)
Ocera Therapeutics (TZYM) Chart for Friday, May, 26, 2017